Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.50
Ask: 14.00
Change: -0.25 (-1.79%)
Spread: 0.50 (3.704%)
Open: 14.00
High: 14.00
Low: 13.75
Prev. Close: 14.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Venture Company

29 Mar 2006 07:02

Angle PLC29 March 2006 For Immediate Release 29 March 2006 ANGLE plc ('ANGLE' or 'the Company') New Venture Company: InnoMatica Ltd ANGLE plc ('ANGLE'), the venture management and consulting company specialisingin the commercialisation of technology, is pleased to announce the launch of itslatest venture company, InnoMatica Ltd ('InnoMatica'). In accordance with ANGLE's Progeny(R) process for creating new ventures,InnoMatica has secured intellectual property that is set to revolutionise theUS$1.2bn per annum global market for percussive power tools by reducing operatorexposure to vibration, the principal cause of medical conditions such asVibration White Finger (VWF). The technology has been developed over ten yearsby a team of leading engineers, academics from the University of Cambridge andmembers of the power tools industry. The scale of the vibration problem is substantial. In 2001, over 35% ofemployer's liability insurance claims were for Hand Arm Vibration Syndrome(HAVS), a debilitating condition caused by exposure to hand transmittedvibration. The Health and Safety Executive (HSE) estimates that there are around300,000 sufferers of VWF, the most common form of HAVS, in the UK, with around 2million people regularly exposed to high levels of vibration. Costs of settlinga single VWF claim can exceed £200,000. Since the implementation throughout Europe of the Physical Agents (Vibration)Directive (approved by the UK Parliament as The Control of Vibration at WorkRegulations, July 2005), employers have been bound to adhere to specific limitson employee exposure to vibration in the workplace. The only method ofsignificantly reducing the vibrations generated by percussive power tools, suchas road breakers, is by increasing the mass of the tool; yet practical andregulatory issues prevent the movement of such heavy tools. As a result,employers have had to either limit the time a single employee may use a tool oruse deliberately underpowered tools in order to comply with the regulations. InnoMatica holds the solution to this problem in the form of its Variable MassTechnology (VMtechnologyTM). This technology reduces tool vibration to a levelthat allows a single operator to use a powerful percussive power tool for up tofour times longer than existing products. This not only removes the need fortime limits or power reduction, but also provides the operator with a much saferand easier to use tool. In accordance with ANGLE's Progeny(R) process for creating new ventures, ANGLE'splan is to build a strong commercial offering, seeking a return on itsinvestment in the medium term. ANGLE expects to invest up to £400,000 in theProgeny(R) venture, which is presently wholly owned by ANGLE. Once InnoMaticahas exercised its option to acquire the technology, ANGLE's equity stake in theCompany will be 61%. ANGLE's Chief Executive, Andrew Newland, said: "The power tools and construction industries are worth US$1.2bn per annum, andthey have long awaited a solution to the injuries caused from vibration powertools. We are delighted to be at the forefront of a technology that dramaticallyenhances productivity, not only solving the financial and legislative issues butalso addressing human safety." Chief Technology Officer of InnoMatica, Dott. Giovanni Bisutti, said: "InnoMatica's technology provides a genuine new standard for health, safety,productivity and operator comfort in percussive power tools. We intend toaddress the major legislative and productivity issues currently facing theindustry." For further information ANGLE plc +44 1483 295830Andrew Newland, Chief ExecutiveStephen Bence, Director of New Ventures Buchanan Communications +44 20 7466 5000Richard Darby, Suzanne Brocks, James Strong, Amy Rajendran Note to editors: About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from officesin the UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found atwww.angleplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Jul 20147:00 amRNSNotification of Preliminary Results
29th Apr 20144:30 pmRNSHoldings in Company
8th Apr 20147:00 amRNSIntellectual Property Update
24th Mar 20147:00 amRNSAppointment of Scientific Adviser
17th Mar 20147:00 amRNSParsortix FDA Submission
24th Feb 20147:00 amRNSUse of Parsortix System with Liver Cancer Patients
18th Feb 20147:00 amRNSParsortix Launch at Circulate Conference in Berlin
30th Jan 20147:00 amRNSInterim Results
13th Jan 20147:00 amRNSCambridge Parsortix Laboratory
10th Jan 20147:00 amRNSNotification of Interim Results and Webcast
7th Jan 20147:00 amRNSAppointment of Scientific Adviser
17th Dec 20137:00 amRNSCE Mark Authorisation
13th Dec 20137:00 amRNSRaises £6.2m from Sale of Geomerics
31st Oct 20133:31 pmRNSResult of 2013 Annual General Meeting
9th Oct 20137:00 amRNSAnnual Report and Accounts and Notice of AGM
31st Jul 20137:00 amRNSPreliminary Results
25th Jul 20137:00 amRNSPositive Evaluation of Parsortix System
19th Jul 20137:00 amRNSNotification of Preliminary Results and Webcast
8th Jul 20137:00 amRNSParsortix Colorectal Cancer Validation
29th May 20137:00 amRNSDirector's Share Transfer
28th May 20137:00 amRNSParsortix Manufacturer Appointed
13th May 20137:00 amRNSPARSORTIX CELL HARVESTING
7th May 20137:00 amRNSParsortix Regulatory Approval Update
28th Feb 20137:00 amRNSParsortix Research Product Launch
15th Feb 201310:56 amRNSDirector's share transfer
31st Jan 20137:01 amRNSFundraising and Director's Dealings
31st Jan 20137:00 amRNSInterim Results
16th Jan 20137:00 amRNSNotification of Interim Results and Webcast
14th Jan 20137:00 amRNSParsortix Cell Recovery
7th Jan 20137:00 amRNSAppointment of NED
18th Dec 20127:00 amRNSParsortix Released to Research Partners
10th Dec 20127:00 amRNSBUSINESS UPDATE
18th Oct 20127:00 amRNSAppointment of Scientific Advisers
17th Oct 20123:45 pmRNSHolding(s) in the Company
11th Oct 20123:39 pmRNSResult of 2012 Annual General Meeting
3rd Sep 20127:00 amRNSIncreased Fundraising
1st Aug 20127:00 amRNSIncreased Fundraising
26th Jul 20127:01 amRNSFundraising
26th Jul 20127:00 amRNSPreliminary Results
24th Jul 20127:00 amRNSNotice of Preliminary Results and Conference Call
27th Jun 20127:00 amRNSOffer Unconditional for Novocellus' Partner Origio
7th Jun 20127:00 amRNSUpdate Re Novocellus' Partner ORIGIO A/S
16th May 20127:00 amRNSGeomerics Milestone Payment
30th Apr 20127:00 amRNSParsortix Design Breakthrough
26th Apr 20127:00 amRNSLaunches New Corporate Website
23rd Apr 20127:00 amRNSParsortix Update for Breast Cancer
17th Apr 20127:00 amRNSParsortix Validation for Ovarian Cancer
11th Apr 20127:00 amRNSNovocellus Embryosure® Trial Started
26th Mar 20127:00 amRNSGeomerics Update
15th Mar 20127:00 amRNSParsortix Validation for Colon Cancer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.